Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call presents a strong financial performance with expected revenue growth from YORVIPATH and SKYTROFA, supported by label expansions and global launches. The company anticipates becoming cash flow positive, which is a positive indicator. The Q&A section highlights confidence in overcoming challenges, with high patient retention rates and strategic market penetration. The overall sentiment is positive, supported by optimistic guidance and strategic growth plans, likely leading to a stock price increase in the short term.

Key Financial Performance

YORVIPATH Revenue EUR 143.1 million in Q3 2025, up from EUR 103 million in Q2 2025. This growth was partially offset by a EUR 3.6 million foreign currency headwind compared to the previous quarter.

SKYTROFA Revenue EUR 50.7 million in Q3 2025, with 3% growth in demand. This was offset by a EUR 1.6 million foreign currency headwind compared to the previous quarter.

Total Revenue EUR 214 million in Q3 2025, including EUR 20 million in collaboration revenue driven by a EUR 13 million milestone related to YORVIPATH and increased partner activity.

R&D Costs EUR 66.9 million in Q3 2025, down from EUR 73.5 million in Q3 2024. This decrease was primarily driven by the completion of certain clinical trials and development activities.

SG&A Expenses EUR 113.4 million in Q3 2025, up from EUR 69.8 million in Q3 2024. This increase reflects the continued impact of global commercial expansion.

Operating Profit EUR 11 million in Q3 2025, signaling positive operating income development.

Net Finance Expense EUR 60.9 million in Q3 2025, primarily driven by noncash items, including a noncash remeasurement loss of financial liabilities of EUR 47.2 million.

Cash and Cash Equivalents EUR 539 million at the end of Q3 2025, up from EUR 494 million at the end of Q2 2025.

You have reached the limit Upgrade to access full content

Get started

Operating Highlights

YORVIPATH: Global revenue of EUR 143 million in Q3 2025, with over 4,250 patients prescribed in the U.S. and expansion into more than 30 countries. Positive patient and physician experiences are driving compliance, and insurance approval rates are around 70%. The product is positioned as a first-in-class therapy for hypoparathyroidism.

SKYTROFA: Revenue of EUR 51 million in Q3 2025. Approved for pediatric and adult growth hormone deficiency in the U.S. and EU. Phase III trials initiated for label expansion to include other growth disorders.

TransCon CNP: Under priority review by the FDA with a PDUFA date of November 30, 2025, and also under review in the EU. Positioned as a leading treatment for children with achondroplasia, with potential approval expected soon.

Geographic Expansion: YORVIPATH is now available in over 30 countries, including recent launches in Japan, Germany, Austria, and Spain. SKYTROFA is also expanding geographically.

Financial Performance: Achieved positive operating income in Q3 2025 with total revenue of EUR 214 million. Cash and cash equivalents increased to EUR 539 million.

R&D and Clinical Trials: R&D costs decreased to EUR 66.9 million due to the completion of certain trials. New trials initiated for label expansion and combination therapies.

Vision 2030: Focused on achieving EUR 5 billion in annual product revenue by 2030 through product launches, label expansions, and geographic growth.

Partnerships: Collaborations with Teijin in Japan, VISEN in China, and Novo Nordisk in metabolic and cardiovascular diseases are progressing well.

You have reached the limit Upgrade to access full content

Get started

Risk or Challenges

Regulatory Approvals and Compliance: The company faces risks related to ongoing and planned regulatory filings, including the timing and results of regulatory decisions for products like TransCon CNP. Delays or unfavorable outcomes could impact commercialization timelines and revenue projections.

Market Penetration and Competition: Despite strong initial uptake, YORVIPATH has only reached less than 5% of the U.S. market for chronic hypoparathyroidism, leaving significant room for competitive pressures. Additionally, SKYTROFA and TransCon CNP face competition in the growth hormone and achondroplasia treatment markets, which could limit market share.

Supply Chain and Global Expansion: The company is expanding YORVIPATH to additional countries, but challenges in achieving full commercial reimbursement and navigating diverse regulatory environments could delay market entry and revenue growth.

Financial Sustainability: While the company achieved positive operating income in Q3 2025, high SG&A expenses due to global commercial expansion and noncash financial liabilities pose risks to sustained profitability.

Currency Fluctuations: Foreign currency headwinds impacted revenue for both YORVIPATH and SKYTROFA in Q3 2025, and continued fluctuations could affect financial performance.

Clinical Trials and Product Development: The success of ongoing clinical trials, such as the PaTHway60 trial and the Phase III basket trial for SKYTROFA, is critical for label expansions and new product launches. Any setbacks could delay commercialization and revenue growth.

You have reached the limit Upgrade to access full content

Get started

Guidance & Outlook

Revenue Growth: Continued revenue growth is expected in the fourth quarter of 2025, primarily driven by the ongoing global launch of YORVIPATH. Longer-term growth for YORVIPATH is anticipated through new patient acquisition, stable pricing, payer mix, and expansion into additional markets. SKYTROFA's revenue growth is expected to continue tracking prescription growth with stable pricing and payer mix, with longer-term growth driven by geographic and label expansion.

Product Approvals and Launches: TransCon CNP is under priority review in the U.S. with a PDUFA date of November 30, 2025, and is also under review in the EU. The company plans to initiate a Phase III trial for combination therapy of TransCon CNP and TransCon Growth Hormone in Q4 2025. YORVIPATH is expected to expand into additional countries in the coming years, with ongoing trials to support higher doses and pediatric use.

Market Expansion: YORVIPATH is now available in over 30 countries, with commercial reimbursement in Germany, Austria, and Spain, and a recent launch in Japan. The company sees significant growth potential in the U.S. market, with only 5% of diagnosed patients currently on YORVIPATH treatment and 80,000-90,000 diagnosed patients in total.

Pipeline Development: The company plans to advance its TransCon technology platform to ensure a constant flow of new programs and products. A Phase III basket trial for SKYTROFA has been initiated, targeting multiple growth disorders. The company also plans to share more details on maximizing YORVIPATH's value in early 2026.

Financial Projections: The company aims to achieve EUR 5 billion or more in annual product revenue by 2030, supported by its current portfolio and pipeline developments.

You have reached the limit Upgrade to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit Upgrade to access full content

Get started

Key Q&A

Q:What are the expectations for the rate of new patient enrollments on YORVIPATH in the U.S.?

A:The company sees a stable number of prescriptions being written in the U.S., excluding the 200-plus patients from the ERP program. Despite concerns about Q3 due to physician vacations, the number of prescriptions remained consistent with Q1 and Q2. In October, more than 400 unique prescriptions were written, indicating a stable launch and a strong foundation for lifelong treatment.

Q:Will there be an impact from seasonality on prescription trends in Q4?

A:Management does not expect seasonality to impact Q4 prescription trends. They were more concerned about Q3 due to summer vacations, but no major impact was observed. They are confident about Q4, citing an increase in prescribers and a broader base of physicians writing prescriptions.

Q:Why is the conversion rate for YORVIPATH only 70%, and how much higher is it expected to go?

A:The 70% approval rate is expected to mature over time, potentially reaching 85% or 90% as seen with other mature brands. The remaining approvals take longer due to the fragmented payer landscape, but the company is optimistic about the clinical value proposition resonating with payers. Early cohorts have a much higher conversion rate, and the company is working to shorten the time frame for approvals.

Q:How is YORVIPATH penetrating different segments of the hypopara market?

A:YORVIPATH is gaining traction among highly symptomatic patients who frequently visit physicians. Efforts are ongoing to reach patients who may not recognize their symptoms or are less motivated to seek care. The company is also targeting various patient groups, including post-surgery, genetic, and immunological cases, and has seen penetration across all these segments.

Q:What is the payer mix and contracting outlook for YORVIPATH?

A:There will be no significant changes in contracting for Q4 or beyond. The product's first-in-class status and clinical value proposition minimize the need for extensive contracting. Any future changes will be minor and aimed at ensuring a smooth patient experience.

Q:What are the expectations for the Phase III trial design for TransCon CNP?

A:The FDA is open-minded about the trial duration, but the regulatory pathway typically requires one year of data. The company has long-term data from the Phase II trial and does not anticipate needing more than one year of controlled treatment data.

Q:What is the outlook for YORVIPATH's gross-to-net (GTN) and seasonality impact?

A:The GTN remains consistent, and no seasonality impact is expected in Q4. The company was more concerned about Q3 but observed no major impact, and they do not foresee any in Q4 either.

Q:What is the patient retention rate for YORVIPATH?

A:Patient retention is very high, with very few patients discontinuing after the first 4-6 weeks. Efforts are being made to improve the titration phase to further enhance retention.

Q:How does the company view the achondroplasia market and TransCon CNP's potential?

A:The company believes the achondroplasia market is underpenetrated, particularly in the U.S., and sees an opportunity to address comorbidities beyond linear growth. They aim to differentiate TransCon CNP by focusing on these broader benefits.

Q:What is the expected revenue split and growth trajectory for YORVIPATH in the U.S. and ex-U.S.?

A:Ex-U.S. revenue is expected to grow by EUR 4-5 million per quarter, with further acceleration in 2026 as more countries are added. The U.S. revenue trajectory is building steadily with a strong foundation of lifelong treatment patients.

Q:What is the company's strategy for TransCon CNP's commercial launch?

A:The strategy includes targeting both de novo patients and switches from daily CNP injections. In markets with high penetration of existing treatments, switches are expected to be significant, while in the U.S., new patient enrollments will dominate due to lower current penetration.

Q:What is the timeline for preclinical data on YORVIPATH's potential for weekly dosing?

A:Preclinical data is expected to be presented at the beginning of the year during a relevant conference.

Q:What is the company's approach to expanding YORVIPATH's label to higher doses?

A:A single-arm safety trial with 18 patients over 6 months is planned to support the label extension for higher doses in the U.S. This is not expected to have a material impact on revenue.

Q:What is the timeline for payer approvals for YORVIPATH?

A:The timeline for payer approvals is improving month by month, with about 50% of approvals occurring within 8 weeks.

Q:What is the company's perspective on the adolescent hypoparathyroid patient market?

A:The adolescent market is smaller but represents a severe disease burden. Many patients come from genetic or immunological backgrounds and face significant developmental challenges. The company sees this as an important area to address despite its smaller size.

Q:Review of Unclear Management Responses

A:Management avoided providing specific details on the expected peak approval rate for YORVIPATH and the exact timeline for achieving it, citing the fragmented payer landscape and variability in timetables. They also did not provide clarity on the final labeling for TransCon CNP, stating they are in late-stage discussions. Additionally, they did not commit to a timeline for discontinuing the reporting of unique patient enrollment metrics, leaving it open-ended.

You have reached the limit Upgrade to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

ASND Transcript

Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript

Positive11-12

Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript

Positive8-9

The earnings call reveals a strong financial performance with significant revenue growth and a successful launch of YORVIPATH. Despite increased SG&A expenses due to global expansion, the company shows a positive outlook with steady patient enrollment and high compliance rates. The Q&A section highlighted management's efforts to improve processes and their optimistic view of market potential. Although some guidance was not provided, the overall sentiment is positive, suggesting a potential stock price increase of 2% to 8% over the next two weeks.

Ascendis Pharma A/S (NASDAQ:ASND) Q1 2025 Earnings Call Transcript

Unknown5-2

Despite strong revenue growth and a new partnership with Novo Nordisk, the earnings miss, high operating expenses, and vague management responses in the Q&A session create uncertainty. The lack of clear guidance on reimbursement and revenue split, alongside cash flow concerns, offset the positive impact of the partnership and product launches. The neutral shareholder return plan further contributes to a neutral sentiment.

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

Unknown5-1

The earnings call presents a mixed sentiment. Positive aspects include strong revenue growth for YorvaPath and collaboration with Novo Nordisk. However, there are concerns about rising operating expenses and supply chain challenges. The Q&A reveals uncertainties in reimbursement and lack of clarity in some responses, leading to a cautious market sentiment. No shareholder return plan was announced, which might disappoint investors. The overall sentiment is neutral, with no major negative or positive catalysts to significantly impact the stock price.

ASND Report

Ascendis Pharma A/S 6-K

6-K

2025-07-28

Ascendis Pharma A/S 6-K

6-K

2025-06-09

Ascendis Pharma A/S 6-K

6-K

2025-06-09

Ascendis Pharma A/S 6-K

6-K

2025-02-12

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.